To study the relationship between the expression of HIF-1a, VEGF and target therapy icotinib response in lung cancer. And to clarify the significance of HIF-1a and VEGF in clinical prognosis of lung cancer patients.

120 lung cancer patients hospitalized from July 2010 to July 2012 in our hospital were selected . All patients with pathologically confirmed non-small cell lung cancer were given icotinib treatment, the levels of HIF-1a and VEGF were monitored using a two-step method. The role of HIF-1a and VEGF in icotinib response was explored. Logisitic regression analysis was used to study the relationship between the expression level HIF-1a and VEGF and clinical prognosis of lung cancer patients.

120 lung cancer patients included CR(22 cases), PR(40 cases), SD(35 cases), PD(23 cases), RR(62 cases), HIF-1a positive expression (32 cases), VEGF positive expression (34 cases). The RR rate of HIF-1a and VEGF positive expression group was significantly lower than corresponding negative expression group, and the difference was statistically significant. Of the 120 NSCLC patients, 64 cases of cutaneous toxicity accounted for 53.3%, 12 cases of mucositis accounted for 10%, 25 cases of diarrhea accounted for 20.8%, 6 cases of abnormal liver function accounted for 5%, peripheral neurotoxicity accounted for 7.5% in 9 cases. However, the incidence of the above side effects showed no significant difference between patients with positive expression of HIF-1a and positive expression of VEGF and negative expression with P>0.05. Logistic analysis suggested that HIF-1a positive expression (P=0.04) and VEGF positive expression (P=0.03), tumor N stage (P=0.04) were independent risk factors for prognosis in patients with non-small cell lung cancer.

HIF-1a positive expression and VEGF positive expression were closely related with icotinib response and prognosis in lung cancer patients.

Lung cancer; HIF-1a; VEGF; icotinib; clinical effect; prognosis